Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Heart Disease Clinical Trials

A listing of Heart Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (246) clinical trials

Eligibility Criteria: Inclusion Criteria:•Age > or equal to 18 years of age•History of non-paroxysmal form of AF as defined by the HRS/EHRA/ECAS Consensus Statement:◦Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically ...

Phase

The treatment options this study will compare are: (1) Hybrid Coronary Revascularization [HCR] (a combination of surgery and catheter procedures to open up clogged heart arteries) and (2) Percutaneous Coronary Intervention [PCI] (catheter procedures alone to open up clogged heart arteries). There are no new or "experimental" procedures being tested ...

Phase

A clinical study of the TAXUS® Liberté® Paclitaxel-Eluting Coronary Stent System which was previously approved by the FDA. Patient Inclusion Criteria: >years of age Patients that need a stent in the coronary arteries Patient Exclusion Criteria: Cannot receive the protocol required dual antiplatelet therapy Currently taking warfarin or similar anticoagulant ...

Phase

The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin compared with placebo, in addition to standard of care, in patients with type II diabetes mellitus and acute coronary syndrome. Patient Inclusion Criteria: In order to participate in this study you need to have a hgA1c level ...

Phase

Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with myocardial infarction (MI). The novel P2Y12 receptor inhibitors prasugrel and ticagrelor are characterized by more prompt, potent, and predictable antiplatelet effects compared with ...

Phase

Myocardial Perfusion Oxidative Metabolism and Fibrosis in HFpEF

The investigators hypothesize that HFpEF is associated with reductions in myocardial blood flow and energy utilization and increased myocardial fibrosis as compared to age and gender matched hypertensive and healthy controls. The investigators will test their hypotheses by comparing measurements of myocardial blood flow, energy utilization, and fibrosis between three ...

Phase

PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements

Fractional flow reserve (FFR) measurement by pressure wire (PW) under hyperemic conditions has become the invasive gold standard for determining the physiologic extent of cardiac ischemia, and which has been validated in several clinical outcomes studies as a way of optimizing case selection for PCI. More recently a microcatheter (MC)-based ...

Phase

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Anti-rheumatic medications decrease cardiovascular mortality in rheumatoid arthritis patients, based mainly on their anti-inflammatory effect. No studies have addressed their effect on preventing recurrent cardiovascular events among non-rheumatic patients. In the pilot phase 200 myocardial infarction patients will be recruited during their index visit to the study hospitals. Patients will ...

Phase

A Randomized Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction

Taken together the results from CHARISMA and PEGASUS-TIMI54, it appears that physicians may consider extending beyond 1 year or reinitiating treatment with clopidogrel 75 mg od or ticagrelor 60mg bid in patients with a prior MI and features of high ischemic and low bleeding risk. Comparative clinical or pharmacodynamic studies, ...

Phase

Treatment of Diabetes in Patients With Systolic Heart Failure

Investigator Initiated Study: Randomized, double-blinded, active-control clinical trial to determine the safety and efficacy of Canagliflozin and Sitagliptin in patients with type 2 diabetes and systolic heart failure (HF). The investigators propose to study the effects of Canagliflozin 100 mg vs Sitagliptin 100 mg (both administered once daily for 12 ...

Phase